Biotechnology Transcriptomics Law In Ukraine.
1. Introduction
Biotechnology Transcriptomics Law in Ukraine concerns the legal regulation of scientific research, medical applications, commercial development and data processing involving transcriptomics.
Transcriptomics is the scientific study of the complete set of RNA transcripts produced by the genome under particular conditions. It helps researchers understand gene expression, disease development, cellular activity, cancer progression, infectious diseases and responses to medicines.
Common transcriptomics technologies include:
RNA sequencing (RNA-seq).
Single-cell RNA sequencing.
Spatial transcriptomics.
Bulk RNA sequencing.
Long-read transcriptomics.
Transcriptome profiling.
Differential gene-expression analysis.
Computational transcriptomics and AI-based RNA analysis.
Ukraine does not currently have a single comprehensive statute specifically entitled the Transcriptomics Law. Instead, transcriptomics activities are regulated through legislation governing personal data, healthcare, biological samples, genomic information, scientific research, intellectual property and clinical investigations.
An important distinction is that transcriptomic data is not automatically identical to genomic data. Genomic information concerns DNA, whereas transcriptomic information concerns RNA expression. Nevertheless, transcriptomic datasets can reveal sensitive information about a person's health, biological characteristics and disease susceptibility.
Consequently, Ukrainian privacy and healthcare legislation is particularly important.
2. Constitutional Framework
The Constitution of Ukraine, 1996, establishes fundamental rights relevant to transcriptomics research.
Article 28 – Human dignity
Scientific research involving human biological material must respect human dignity and physical integrity.
Article 32 – Privacy and personal information
Article 32 protects private and family life and restricts the collection, storage, use and dissemination of confidential personal information without consent, subject to legally established exceptions.
Article 34 – Freedom of information
Scientific institutions enjoy freedom to collect, use and disseminate information, subject to constitutional restrictions protecting privacy, health and other legitimate interests.
Article 49 – Right to healthcare
The constitutional right to healthcare supports the development of medical research while requiring respect for patients' rights.
These constitutional provisions establish an important balance between scientific progress and individual privacy.
Legal significance: A Ukrainian research institution cannot justify unrestricted access to patients' transcriptomic information merely by claiming that its research has scientific value.
hudoc.echr.coe.int+1
3. Law on Protection of Personal Data, 2010
The Law of Ukraine No. 2297-VI, On Protection of Personal Data, dated 1 June 2010, is one of the most important legal instruments governing transcriptomics.
Transcriptomic datasets may contain identifiable or indirectly identifiable health information.
Important provisions
Article 6 – General principles of personal-data processing
Processing must comply with lawful, fair and proportionate purposes.
For transcriptomics research, this means:
Research purposes must be identified.
Data collection must be proportionate.
Information should not be retained unnecessarily.
Further processing must comply with applicable legal requirements.
Article 7 – Special categories of personal data
Article 7 provides special protection for sensitive information, including health, biometric and genetic data.
Where transcriptomic information reveals or constitutes health-related or genetic information, the applicable special-data protections must be considered.
Article 8 – Rights of data subjects
Individuals have rights concerning their personal information, including access and other rights established by law.
Article 24 – Protection of personal data
Data controllers must implement organisational and technical safeguards against unlawful processing, loss, destruction and unauthorised access.
Example
A Ukrainian biotechnology company collects RNA-sequencing information from 5,000 cancer patients.
The company must establish an appropriate legal basis for processing, explain the research purposes, protect identifiable information and control access to the resulting datasets.
It cannot automatically sell identifiable patient transcriptomic information to pharmaceutical companies simply because the information was collected during scientific research.
zakon.rada.gov.ua+2
4. Cabinet Resolution No. 999 of 2024: Biological Samples and Biobanking
Particularly important legislation
One of the most significant developments for Ukrainian transcriptomics regulation is Cabinet of Ministers Resolution No. 999 of 30 August 2024.
It approves the Procedure for the Collection, Storage and Use of Human Biological Samples for Research Purposes.
The regulation entered into force on 4 September 2024.
This instrument is particularly relevant because transcriptomics research frequently requires biological materials such as:
Blood samples.
Tissue samples.
Tumour biopsies.
Bone-marrow samples.
Cellular material.
Other human biological specimens.
Major regulatory areas
A. Collection of biological samples
Research institutions must follow the prescribed requirements for collecting human biological samples.
B. Storage of samples
Biological samples must be managed according to the applicable research and storage requirements.
C. Associated information
The regulation addresses not only biological specimens but also associated research data.
D. Biobank activities
A biobank may be a legal entity or a separate structural unit of a legal entity carrying out biobanking activities.
E. Research purposes
The regulation provides a legal framework for collecting, storing and using biological samples for scientific research and healthcare development.
Application to transcriptomics
Suppose a Ukrainian university establishes a biobank containing 10,000 tumour samples.
Researchers subsequently use those samples for RNA sequencing to identify molecular patterns associated with breast cancer.
The collection, storage and research use of the samples must be assessed under Resolution No. 999, together with applicable healthcare, consent and personal-data requirements.
An important limitation is that Resolution No. 999 excludes certain activities, including medicinal-product clinical trials, from its scope. Such activities must be assessed under their separate regulatory framework.
від 30.08.2024 № 999+2
5. Law on State Registration of Human Genomic Information, 2022
Ukraine adopted Law No. 2391-IX, On State Registration of Human Genomic Information, on 9 July 2022.
It entered into force on 6 February 2023.
This legislation regulates the state registration of human genomic information in specified circumstances.
Principal objectives
Identification of individuals in legally prescribed circumstances.
Regulation of biological-material collection for genomic registration.
Establishment of procedures for handling genomic information.
Protection of individual rights during genomic registration.
Judicial challenges to unlawful actions by relevant authorities.
Relationship with transcriptomics
The law primarily concerns genomic information rather than the entire transcriptome.
However, transcriptomics research may involve genomic information alongside RNA-expression datasets.
For example, a researcher may combine DNA sequencing and RNA sequencing to investigate hereditary cancer.
The DNA-related information may fall within the specific genomic-registration framework where its statutory conditions are met. The RNA-expression information must be assessed under the relevant privacy, health-data and research provisions.
It would therefore be legally incorrect to assume that every RNA-sequencing dataset automatically becomes subject to mandatory state genomic registration.
від 09.07.2022 № 2391-IX+1
6. Healthcare Law and Informed Consent
The Law of Ukraine No. 2801-XII, Fundamentals of Ukrainian Legislation on Healthcare, dated 19 November 1992, provides important protections for patients participating in transcriptomics research.
Article 39 – Patient information
Patients have rights concerning information about their health and medical investigations.
Researchers and healthcare professionals should provide understandable information concerning relevant medical procedures and investigations.
Article 39-1 – Confidentiality of health information
Patients have the right to confidentiality concerning their health status and medical information.
Article 40 – Medical secrecy
Medical personnel and other persons who obtain confidential medical information through their professional or official duties must not disclose it except in legally authorised circumstances.
Article 43 – Consent to medical intervention
Consent requirements are relevant when transcriptomic testing involves medical intervention or diagnostic procedures.
For research involving human participants, informed consent and applicable research-ethics requirements must also be observed.
Example
A hospital collects tissue from a patient undergoing surgery and uses it for transcriptomic analysis.
The legal assessment must distinguish:
Consent to surgery.
Consent to diagnostic testing.
Consent to additional research use.
Consent or another lawful basis for processing personal information.
Permission for subsequent sharing or commercial use.
Consent to medical treatment should not automatically be interpreted as unrestricted consent to future commercial transcriptomics research.
zakon.rada.gov.ua+2
7. Clinical Trials and Transcriptomics
Transcriptomics is increasingly important in clinical trials because RNA-expression profiles can help researchers understand how patients respond to medicines.
Examples include:
Cancer drug-response research.
Vaccine-response studies.
Immunotherapy investigations.
Biomarker validation.
Drug-resistance research.
Personalised medicine.
Ukraine's medicinal-product legislation includes Law No. 123/96-VR, On Medicinal Products, and Ministry of Health regulatory procedures governing clinical trials.
Transcriptomic testing connected with a medicinal-product clinical trial must be assessed under the applicable clinical-trial requirements.
Principal legal obligations
Research approval: Applicable regulatory and ethics requirements must be satisfied.
Participant protection: Clinical research must respect participants' rights and safety.
Data confidentiality: Patient information must be protected.
Research documentation: Investigators must maintain appropriate records.
Scientific integrity: Research findings must be accurately documented and reported.
Legal problem
A pharmaceutical company conducting a Ukrainian clinical trial may wish to transfer RNA-sequencing datasets to a foreign research centre.
The company must examine the legal basis for the original collection, the permitted research purpose, international data-transfer requirements and applicable contractual safeguards.
8. Intellectual Property Rights in Transcriptomics
Transcriptomics research can generate commercially valuable discoveries.
Examples include:
Novel RNA biomarkers.
Diagnostic techniques.
RNA-expression algorithms.
Disease-classification methods.
Computational analysis software.
Therapeutic applications based on RNA-expression findings.
Ukraine's principal intellectual-property legislation includes the Law on Protection of Rights to Inventions and Utility Models and the Law on Copyright and Related Rights.
Patent protection
A patent may potentially protect a qualifying technical invention arising from transcriptomics research.
However, scientific discoveries, naturally occurring biological phenomena and raw observations are not automatically patentable inventions.
A claimed invention must satisfy the applicable requirements, including novelty, inventive step and industrial applicability, subject to statutory exclusions.
Copyright protection
Copyright may protect original software and qualifying original research materials.
However, copyright does not automatically give exclusive ownership over underlying biological facts or scientific discoveries.
Ownership disputes
Suppose a university researcher discovers a new RNA biomarker using patient samples.
Potential legal questions include:
Who owns the resulting invention?
Does the researcher have inventor rights?
Does the university own employment-related intellectual property?
What contractual rights belong to a pharmaceutical sponsor?
Were the biological samples lawfully collected and used?
These questions require separate consideration of patent law, employment arrangements, research agreements and patient rights.
9. Artificial Intelligence and Computational Transcriptomics
AI-based transcriptomics is becoming important in Ukrainian biomedical research.
AI systems can analyse large RNA-sequencing datasets to identify molecular patterns and predict disease-related gene-expression changes.
However, these applications create several legal concerns.
| Legal issue | Regulatory concern |
|---|---|
| AI profiling | Unlawful processing of health information |
| Automated diagnosis | Medical-device and healthcare requirements |
| Data security | Unauthorised access to RNA datasets |
| Algorithmic discrimination | Unfair treatment based on biological information |
| Data ownership | Disputes concerning research and commercial rights |
| Model transparency | Reliability and scientific reproducibility |
| International processing | Cross-border personal-data compliance |
Where an AI system qualifies as medical-device software, applicable Ukrainian medical-device requirements must also be considered.
A research algorithm should not automatically be treated as a clinically approved diagnostic instrument.
10. Cross-Border Transcriptomics Research
International cooperation is essential for large-scale transcriptomics projects.
Ukrainian research institutions may cooperate with laboratories in:
Germany.
France.
Poland.
United States.
United Kingdom.
Japan.
Such cooperation may involve the transfer of RNA samples, sequencing files, patient information and research findings.
Important legal issues
A. International data transfers
The Law on Protection of Personal Data establishes requirements relevant to transferring personal data outside Ukraine.
B. Research agreements
Institutions should specify the permitted purposes of data use and responsibilities of each party.
C. Biological-material export
The transfer of human biological samples must be assessed under applicable Ukrainian requirements and any other relevant export, customs and research regulations.
D. Confidentiality
Foreign research partners must respect applicable confidentiality obligations and data-protection safeguards.
E. Intellectual property
Research agreements should clarify ownership, licensing, publication and commercialisation rights.
A further consideration is that GDPR may apply to processing activities falling within its territorial scope, particularly where European research partners process identifiable or pseudonymised health data.
11. Important Case Laws and Judicial Decisions
There is an important limitation in Ukrainian transcriptomics jurisprudence: the following cases establish relevant legal principles concerning privacy, genetic information and medical confidentiality, but they are not judgments directly deciding RNA-sequencing or transcriptomics disputes.
Case 1. Constitutional Court of Ukraine – Decision No. 2-rp/2012
Direct Ukrainian constitutional authority
Date: 20 January 2012.
Subject: Constitutional interpretation of Articles 32 and 34 of the Constitution of Ukraine.
Legal principle:
The Constitutional Court explained that confidential information concerning a person's private and family life cannot ordinarily be collected, stored, used or disseminated without consent.
Interference without consent is permissible only in circumstances established by law and for constitutionally recognised interests.
Application to transcriptomics:
A research institution collecting identifiable RNA-expression information must respect constitutional privacy protections.
The decision is particularly relevant where transcriptomic information reveals sensitive medical conditions.
Constitutional Court of Ukraine+2
Case 2. Surikov v. Ukraine
Court: European Court of Human Rights.
Application No.: 42788/06.
Judgment date: 26 January 2017.
Legal issue: Collection, retention and disclosure of sensitive medical information.
The applicant challenged the handling of information concerning his historical mental-health status by his employer.
The European Court examined the protection of sensitive medical information under Article 8 of the European Convention on Human Rights.
The Court identified problems arising from prolonged retention and disclosure of health information for purposes unrelated to its original collection.
Legal principle:
Medical information requires effective protection, and its retention and subsequent use must be proportionate and justified.
Application to transcriptomics:
RNA-expression data may reveal information about an individual's disease status.
A biotechnology company should not retain identifiable transcriptomic information indefinitely or use it for unrelated purposes without an appropriate legal basis.
Bailii+1
Case 3. Supreme Court of Ukraine – Case No. 205/9115/19
Decision date: 29 June 2022.
Proceeding No.: 61-10283св21.
Subject: Disclosure of confidential medical information.
A medical professional disclosed information concerning a patient's HIV-positive status in a referral to another medical professional without satisfying the applicable consent requirements.
The Civil Cassation Court within the Supreme Court overturned the lower courts' decisions and awarded moral damages in part.
Legal principle:
A patient's medical confidentiality cannot be disregarded merely because a third party already knows the patient's diagnosis.
Disclosure must satisfy the applicable legal requirements.
Application to transcriptomics:
If a hospital transfers RNA-sequencing results revealing a patient's HIV-related biological information to an external researcher without an appropriate legal basis, this may raise comparable confidentiality issues.
court.gov.ua+1
Case 4. S. and Marper v. United Kingdom
Court: European Court of Human Rights.
Application Nos.: 30562/04 and 30566/04.
Judgment date: 4 December 2008.
Subject: Retention of DNA profiles and biological samples.
The applicants challenged the indefinite retention of their fingerprints, DNA profiles and cellular samples.
The Grand Chamber found a violation of Article 8 of the European Convention on Human Rights.
Legal principle:
The retention of biological material and sensitive identifying information requires appropriate safeguards and proportionality.
Application to transcriptomics:
Although DNA profiling and RNA sequencing are scientifically different, the case provides useful guidance on privacy risks associated with retaining identifiable human biological material.
Law Gratis+1
Case 5. Z v. Finland
Court: European Court of Human Rights.
Application No.: 22009/93.
Judgment date: 25 February 1997.
Subject: Medical confidentiality and HIV-related information.
The Court recognised that protecting the confidentiality of medical information is fundamental to privacy and the relationship between patients and healthcare professionals.
Application to transcriptomics:
Where transcriptomic analysis reveals HIV status, hereditary disease indicators or other sensitive health information, confidentiality must be taken seriously.
This judgment is a comparative human-rights authority rather than a Ukrainian domestic judgment.
Law Gratis+1
12. Major Legal Challenges in Ukraine
Several important legal challenges arise from the development of transcriptomics.
| Challenge | Legal implications |
|---|---|
| Unauthorised RNA sequencing | Consent and lawful research use |
| Genetic and health-data exposure | Privacy and confidentiality |
| Biobank sample ownership | Donor rights and institutional responsibilities |
| Commercialisation of RNA biomarkers | Patent and contractual rights |
| AI-based disease prediction | Medical and data-protection compliance |
| International data sharing | Cross-border transfer requirements |
| Long-term sample retention | Storage limitations and donor rights |
| Research involving minors | Additional consent and participant-protection requirements |
| Scientific misconduct | Research integrity and civil liability |
| Unauthorised secondary research | Purpose limitation and legal basis |
13. Regulatory Authorities and Institutions
Several Ukrainian institutions have responsibilities relevant to biotechnology and transcriptomics.
Ministry of Health of Ukraine: Healthcare policy and relevant medical regulation.
Ukrainian Parliament: Enactment of legislation governing research, healthcare and personal data.
Parliament Commissioner for Human Rights: Oversight of personal-data protection and human rights.
State Expert Centre of the Ministry of Health: Relevant regulatory and expert functions concerning medicinal products and clinical trials.
Ukrainian courts: Judicial protection of privacy, medical confidentiality and other legal rights.
Research ethics committees: Ethical assessment of applicable biomedical research.
14. Practical Compliance Framework for Transcriptomics Laboratories
A Ukrainian biotechnology laboratory should consider the following compliance measures:
Identify whether the project involves human biological samples.
Establish the lawful basis for collecting and processing personal data.
Obtain appropriate informed consent where required.
Comply with Cabinet Resolution No. 999 when its scope applies.
Protect identifiable RNA-sequencing information.
Establish appropriate sample-storage procedures.
Restrict access to authorised researchers.
Establish rules for secondary research.
Assess international data transfers.
Protect commercially valuable research results.
Maintain accurate research records.
Establish procedures for responding to data breaches.
15. Conclusion
Biotechnology Transcriptomics Law in Ukraine is an emerging interdisciplinary field involving constitutional law, medical law, personal-data protection, biobanking, intellectual property and scientific research regulation.
The most important legal instruments include:
Constitution of Ukraine, Article 32.
Law No. 2297-VI on Protection of Personal Data, 2010.
Law No. 2801-XII on Healthcare, 1992.
Cabinet Resolution No. 999 of 2024.
Law No. 2391-IX on State Registration of Human Genomic Information, 2022.
Applicable medicinal-product and clinical-trial regulations.
The most relevant judicial authorities include Constitutional Court Decision No. 2-rp/2012, Surikov v. Ukraine, and Supreme Court Case No. 205/9115/19.
The central legal principle is that scientific innovation in transcriptomics must operate within a framework protecting human dignity, medical confidentiality, biological-material rights and personal information.
16. Important Legal Research Sources
For further academic and legal research:
Official Ukrainian legislation – Personal Data Protection and Healthcare legislation.
Cabinet Resolution No. 999 of 2024 – Biological Samples for Research.
Law No. 2391-IX – State Registration of Human Genomic Information.
Constitutional Court of Ukraine – Privacy jurisprudence.
Supreme Court of Ukraine – Medical Confidentiality Judgment.
Legal regulation of genetic information and genetic testing in Ukraine – Academic research, 2025.
Academic qualification: This analysis distinguishes legislation directly governing biological samples and personal data from comparative judicial decisions. No reported Ukrainian judgment specifically deciding the legality of transcriptome sequencing has been identified in the cited authorities. Legal provisions and their current amendments should be checked against the official Ukrainian legislation database before litigation or regulatory reliance.

comments